Erlotinib vs Rituximab

Erlotinib vs Rituximab: Overview

This comparison examines the pharmacological differences between Erlotinib and Rituximab.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Rituximab — 22 days.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Erlotinib — Small molecule; Rituximab — Antibody.